debt_leverage_profile
0.20x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; BeOne carries minimal long-term debt, funded primarily by equity and milestone payments; 200bps rate rise negligibly impacts P&L but raises hurdle rates for future equity raises
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) China API manufacturing concentration (BeiGene's Guangzhou/Suzhou facilities); 2) U.S.-China geopolitical tension threatening cross-border API and clinical supply flows
Inferred
Agent_Inference
international_expansion_readiness
Top-3 markets: China (CNY devaluation risk high, ~40% revenue), U.S. (USD functional currency, minimal FX risk), Europe (EUR exposure moderate ~10%); CNY depreciation materially compresses reported revenue
Inferred
Agent_Inference
geographic_footprint
China CNY devaluation of 10% would reduce reported revenue ~4%; EUR exposure adds ~1-2% sensitivity; USD is functional currency, limiting consolidated FX translation risk substantially
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
BeiGene collaboration represents historically dominant single-partner dependency; zanubrutinib API manufacturing concentrated in proprietary BeiGene China facilities—non-substitutable short-term, high lock-in risk
Inferred
Agent_Inference
business_model_type_primary
Pharma/biotech product commercialization; cloud disruption risk is moderate—clinical data systems and ERP could face 60-90 day migration disruption but no direct patient-care termination risk
Inferred
Agent_Inference
business_model_type_secondary
Royalty and milestone receipts from licensing; cloud termination would disrupt back-office and regulatory submission systems but revenue flow from partner sales would continue uninterrupted
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; BeOne uses standard pharma IT stack (Veeva, SAP); no proprietary API ecosystem lock-in; switching costs concentrated in regulatory data migration, not technology interfaces
Inferred
Agent_Inference
howey_test_risk_index
Fails Howey Test cleanly; revenue derived from FDA-approved drug product sales and licensing milestones—not investment contracts; securities law reclassification risk effectively zero
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate-high; clinical trial data held across China, EU, and U.S. jurisdictions; GDPR Article 46 transfer mechanism exposure for EU patient data; CCPA applies to U.S. commercial operations; China PIPL adds complexity
Inferred
Agent_Inference
antitrust_exposure_flag
Low-moderate; BTK inhibitor market has Abbvie (ibrutinib) and AstraZeneca (acalabrutinib) competitors; no dominant market share triggering DOJ/FTC concern; EU pricing negotiations pose reimbursement rather than antitrust risk
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~70% transactional (product net sales of zanubrutinib); ~30% recurring/contractual (royalties, collaboration milestones); no subscription revenue; highly dependent on prescription volume growth
Inferred
Agent_Inference
monetization_vector
Primary: oncology drug net sales (zanubrutinib); Secondary: collaboration royalties and milestone payments from BeiGene and other partners; tertiary: future pipeline asset licensing
Inferred
Agent_Inference
pricing_architecture
WAC-based specialty pharma pricing (~$14,000-$16,000/month U.S. list price); vulnerable to IRA Medicare drug price negotiation post-2026; gross-to-net discount ~25-30%; international pricing 40-60% below U.S.
Inferred
Agent_Inference
pricing_power_rating
Moderate-high near-term; differentiated efficacy/tolerability data supports premium; IRA negotiation risk and PBM rebate pressure cap upside; international reference pricing creates downward anchor; rating: 6.5/10
Inferred
Agent_Inference
target_gross_margin_bracket
87.5% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; prescription drugs require physician authorization and pharmacy dispensing—no digital free-tier leakage; churn risk tied to disease progression, generic entry post-patent, or competitive label updates
Inferred
Agent_Inference
headcount_cost_structure
Sublinear at scale; commercial infrastructure (MSLs, sales force ~500+) scales modestly with new indications; R&D headcount grows with pipeline but manufacturing outsourced; doubling revenue requires ~30-40% headcount growth
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of incremental prescriptions is low (COGS ~15-20% of net sales); primary growth investment is sales force and clinical trials; gross margin expansion expected as fixed costs leverage with volume
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; BeOne operates as a direct pharmaceutical company without franchise or distributor network in primary markets; specialty pharmacy channel managed through limited specialty distributor agreements
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC efficiency improves significantly; oncologist KOL network largely established; incremental indication launches leverage existing commercial infrastructure; estimated CAC/LTV ratio improves from ~1:8 to ~1:15
Inferred
Agent_Inference
network_effect_present
No traditional network effects; competitive moat from clinical data, physician familiarity, and patient outcomes data creates weak data network effect; durability moderate—erodes with competitive label updates
Inferred
Agent_Inference
asset_efficiency_ratio
5.1% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Tier 1 recession-resistant; oncology treatments are non-discretionary; CLL/MCL patients cannot defer therapy; insurance and government payer coverage insulates volume; revenue highly inelastic to macroeconomic cycles
Inferred
Agent_Inference
customer_segment_primary
Oncologists and hematologists prescribing for CLL, MCL, WM indications; U.S. accounts for ~55% of revenue; top-10 academic cancer centers represent disproportionate early adoption
Inferred
Agent_Inference
customer_segment_secondary
Specialty pharmacies and hospital systems as distribution channel customers; payer/PBM concentration risk—top-3 PBMs control ~80% of U.S. formulary access, creating reimbursement negotiation leverage against BeOne
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
3.5% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001651308
High
SEC-EDGAR
ticker
ONC
High
SEC-EDGAR